Clinical efficacy of anti‐amyloid antibodies in apolipoprotein E ε4 homozygotes: A Bayesian reanalysis of lecanemab and donanemab phase 3 results

Abstract INTRODUCTION We aimed to determine the clinical efficacy of treating apolipoprotein E (ApoE) ε4 homozygotes with recently approved anti‐amyloid antibodies. METHODS Data were derived from supplementary analyses in the regulatory studies Clarity (lecanemab) and TRAILBLAZER‐ALZ2 (donanemab). W...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Stefan Teipel, Yi Tang, Ara Khachaturian
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2025-04-01
coleção:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Assuntos:	Alzheimer's disease ApoE ε4 Bayesian reanalysis CDR‐SB clarity TRAILBLAZER‐ALZ2
Acesso em linha:	https://doi.org/10.1002/trc2.70083
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!